ORION CORPORATION INTERIM REPORT 1–9/2025 28 OCTOBER 2025 at 12:00 EET Orion Group Interim Report January–September 2025 July–September 2025 Highlights Net sales totalled EUR 423.2 (July–September 2024: 471.3) million Operating profit was EUR 121.0 (202.0) millionNet sales and operating profit of the comparison period include EUR 130 million of major milestone paymentsBasic earnings per share were EUR 0.68 (1.14)Cash flow from operating activities per share was EUR 0.55 (0.48)The outlook for 2025 has been ...

The CNBC app, global market news in one place. Customizable sections and personalized alerts, stocks tracking, interactive charts and market insights, all in your hands. Stay connected, stay informed.Download the CNBC app today. >> Welcome to Sportbox Europe. I'm Karen show with Juliana Tatlebomb.These are your headlines in corporate news. Nevada says it's well on track to achieve its guidance for the year as Q3 operating income surges by a quarter, countering the impact of generic drug erosion in the Unite ...

Pollon Life, a Chinese maker of stem cell drugs, has filed confidentially for a Hong Kong IPO that could raise about $300 million or more https://t.co/w6Fz4xwVk5 ...

Core Insights - Swiss drugmaker Novartis is planning to enhance its direct-to-patient platform by adding more medicines, with the platform set to launch in the U.S. next month [1] Company Developments - CEO Vas Narasimhan indicated that the company is actively exploring options for expanding its medicine offerings on the new platform [1]

Core Insights - Novartis is acquiring Avidity Biosciences for approximately $12 billion, marking its largest deal in a decade, to enhance its drug pipeline and offset competition from generics [2] - The company reported a 7% increase in third-quarter net sales to $13.9 billion, with operating income rising 27% to $5.46 billion, slightly exceeding analyst expectations [3] - Novartis has maintained its sales growth guidance at a "high single digit" percentage and adjusted operating income growth at a "low teens" percentage despite market pressures [5] Financial Performance - The third-quarter net sales reached $13.9 billion, reflecting a 7% increase [3] - Operating income for the quarter increased by 27% to $5.46 billion, surpassing analyst expectations [3] - Key drugs such as Kisqali, Pluvicto, Scemblix, and Kesimpta contributed to high double-digit revenue growth [4] Strategic Moves - Novartis has been actively acquiring companies, with over 35 acquisitions in the past year to strengthen its market position [2] - The acquisition of Avidity is expected to provide access to promising experimental drugs, with two of Avidity's leading drugs projected to generate billions in sales by 2030 [1] - The company is focused on continuous acquisition to find the next "great asset" in the pharmaceutical sector [2] Market Challenges - Novartis faces challenges from generics competition, which has negatively impacted revenue by 7 percentage points due to loss of exclusivity for key drugs [6] - Revenue deductions in the U.S. due to pricing adjustments contributed an additional negative impact of 2 percentage points [6] - The company is closely monitoring global tariff updates and U.S. drug pricing policies that could affect its operations [6][7] Future Outlook - Analysts expect Novartis to potentially enter similar "most favoured nation" agreements as Pfizer and AstraZeneca, which could impact earnings from 2026 onwards [8] - Novartis has committed to eliminating price differentials between U.S. and other industrialized nations for its drugs [8] - The company is not expected to be affected by a 100% tariff on branded pharmaceuticals due to its significant investment in U.S. infrastructure [9]

Core Insights - The drugmaker reported a third-quarter profit of $3.93 billion, driven by increased sales of key drugs which helped to mitigate the impact of patent expirations [1] Financial Performance - The third-quarter profit reached $3.93 billion, indicating strong financial performance despite challenges [1] - Higher sales for key drugs were a significant factor contributing to the profit [1] Market Impact - The company successfully offset losses from patent expirations through strategic sales increases [1]

Market Overview - European stocks are expected to open flat to higher, with the U.K.'s FTSE index slightly up, Germany's DAX and France's CAC 40 down by 0.2%, and Italy's FTSE MIB just below the flatline [1] Federal Reserve Meeting - The U.S. Federal Reserve's two-day meeting begins on Tuesday, with a 96% chance of a 25 basis-point rate cut anticipated by the market [2] - Traders are looking for signals from Fed Chair Jerome Powell regarding another potential rate cut at the final meeting of the year in December due to concerns about a weakening labor market [2] Economic Data and Geopolitical Concerns - The Fed is facing an economic data blackout due to the ongoing U.S. government shutdown, with limited recent data available, including last week's inflation report [3] - Geopolitical issues, particularly the U.S.-China trade dispute, are also significant for investors, with a meeting scheduled between President Trump and President Xi Jinping in South Korea to address trade tensions [3] Trade Negotiations - Both the U.S. and China appear to be in a conciliatory mood, having agreed on a framework for a potential trade deal that includes topics such as rare earths export restrictions, soybean purchases, and TikTok [4] - President Trump expressed optimism about reaching a deal with President Xi during their upcoming meeting at the APEC Summit [4] Earnings Reports - Key earnings reports in Europe on Tuesday include Novartis, BNP Paribas, Capgemini, Air Liquide, Iberdrola, ASM International, and Logitech [5] - HSBC, Europe's largest lender, reported third-quarter profits that exceeded expectations [5]

Core Points - Novartis announced the expiration of its tender offer to acquire Tourmaline Bio, Inc. at a price of $48.00 per share, which ended on October 27, 2025 [1][2] - Approximately 24,030,382 shares were validly tendered, representing about 92.94% of the outstanding shares prior to the expiration [2] Company Information - Novartis is an innovative medicines company focused on improving and extending lives through its products, reaching over 300 million people globally [5]

Novartis profit rose last quarter, boosted by new cancer drugs https://t.co/XDZFh4UkmE ...

Market Overview and Key Insights - The A-share market showed an overall upward trend last week, with major indices rebounding: CSI 300 rose by 2.9%, CSI 500 by 3.5%, CSI 1000 by 3.3%, ChiNext 50 by 9.5%, and Sci-Tech 50 by 7.3% [1] - The average daily trading volume in the A-share market was around 1.8 trillion yuan, indicating a slight decrease in market activity [1] - Market hotspots exhibited rapid rotation, shifting from computing hardware and coal to optical modules, aerospace, and oil and gas [1] - The current market style emphasizes structural opportunities, with a mid-to-long-term investment direction suggested to align with the 14th Five-Year Plan, focusing on policy support and industrial resonance [1] Focus on ChiNext - The ChiNext serves as a direct financing platform for growth-oriented innovative enterprises, particularly in the "three innovations and four new" sectors [1] - The ChiNext 50 Index focuses on four key sectors: information technology, new energy, financial technology, and pharmaceuticals, showcasing pure technology growth attributes [1][5] ChiNext 50 Index Composition - The ChiNext 50 Index has a significant weight in the information technology sector, comprising 44%, with 17% allocated to optical modules [6] - The optical module sector experienced a substantial rebound last week, driven by positive market sentiment and several favorable developments [6] - Key developments in the optical module market include an upward revision in demand for 1.6T optical modules and a projected supply shortage for high-speed optical modules [6] New Energy Sector Insights - The new energy photovoltaic sector saw a slight increase last week, with ongoing policy guidance aimed at promoting industry self-discipline [6] - The demand for energy storage is expected to grow, supported by the 14th Five-Year Plan, while battery prices stabilize [6] - Long-term trends indicate an improvement in supply-demand dynamics for new energy photovoltaics, with reduced silicon material inventory pressure and cost advantages for HJT components [6] Pharmaceutical Sector Overview - The pharmaceutical sector experienced a slight adjustment last week, with reduced funding attention and a potential technical correction [7] - The internationalization of innovative drugs is accelerating, with significant license-out transactions expected to reach 920.3 million USD by the third quarter of 2025 [7] - Policy moderation is evident, with a narrowing price reduction in procurement agreements, indicating a potential turning point for the medical device sector [7] ChiNext 50 ETF Performance - The ChiNext 50 ETF (code: 159949) focuses on leading companies in high-value sectors such as new energy vehicles, biomedicine, electronics, photovoltaics, and internet finance [8] - The ETF has a robust liquidity profile, with an average daily trading volume of 1.52 billion yuan over the past year, ranking among the top ETFs on the Shenzhen Stock Exchange [8] - The latest fund size of the ChiNext 50 ETF is 26.307 billion yuan, making it one of the largest funds tracking the ChiNext-related indices [8]